Limited Course Of Thalidomide Effective In Treating AIDS-Related Mouth Ulcers

May 22, 1997

Thalidomide effectively heals severe mouth and throat ulcers in people with HIV infection, according to a study supported by the National Institute of Allergy and Infectious Diseases (NIAID) and reported in the May 22, 1997, issue of The New England Journal of Medicine.

"For the many patients with HIV infection who suffer from these ulcers, eating can be excruciatingly painful, which exacerbates wasting and debilitation," says Division of AIDS Director Jack Y. Killen, M.D. "Thalidomide is the first treatment shown in a scientific study to heal these ulcers, but the course should be carefully monitored and limited in its duration because of the drug?s potential toxicity."

The ulcers of 55 percent of the patients receiving four weeks of thalidomide healed completely, compared to healing in only 7 percent of the patients receiving placebo. Almost all (90 percent) of those receiving thalidomide had at least partial healing.

The AIDS Clinical Trials Group (ACTG), a network of clinical trial sites supported by NIAID, conducted this study, called ACTG 251. Baseline and weekly health evaluations of study volunteers included a quality-of-life questionnaire to assess pain and discomfort during eating. Results from these questionnaires showed that the thalidomide group improved much more than the placebo group in regaining comfort while eating.

"Thalidomide appears to have great potential as a therapy for HIV-infected patients who have severe oral aphthous ulcers," says Lawrence Fox, M.D., Ph.D., one of two NIAID authors, "but only when administered by a physician who is vigilant for the possible serious side effects, including irreversible, painful peripheral nerve damage, rash and birth defects.

Patients experienced only minimal adverse effects while they were taking thalidomide. Seven patients reported drowsiness and seven had rashes. The authors caution, however, that those patients who received thalidomide showed a small, but statistically significant increase in HIV ribonucleic acid (RNA) blood levels from the baseline through the fourth week of the study as compared to patients receiving placebo. "There is not sufficient information, however, to judge whether this increase is of any clinical significance," says study director Jeffrey M. Jacobson, M.D., of the Departments of Medicine at both Bronx Veterans' Affairs Medical Center and Mount Sinai School of Medicine, New York.

A second reason for caution, according to the study results, is that patients taking thalidomide had elevated plasma levels of tumor necrosis factor-alpha, a substance released from phagocytes and from some T cells during the immune response and known to provoke HIV replication and expression from infected cells. This was unanticipated because earlier studies had reported that thalidomide inhibited production of tumor necrosis factor-alpha. These patients also showed increased soluble tumor necrosis factor-alpha receptor levels, a phenomenon shown to be associated with clinical progression of HIV disease.

Scientists at 19 sites conducted the double-blind, randomized, placebo-controlled study. Of 57 volunteers, 29 received thalidomide. The remaining patients received placebo, but were offered open-label thalidomide at the endpoint of the study. All patients in the study were HIV-positive and had oral or throat ulcers for at least two weeks before the start of the study.

At each of the study sites, physicians evaluated patients in initial screenings, in baseline physical examinations, and then weekly throughout the study. Because of thalidomide's well-known ability to cause severe birth defects, every precaution was taken to prevent pregnancy, and pregnancy tests were given weekly to women of childbearing age. Each baseline and weekly evaluation included an assessment of nerve function, (peripheral sensory nerve disorders are a known complication of longer-term thalidomide treatment), laboratory analyses of blood cells, serum chemistries and serum thalidomide levels, and evaluation of liver and kidney function.

The National Center for Research Resources supported this study in part through the General Clinical Research Center Units. Andrulis Pharmaceutical Corporation of Beltsville, Md., provided thalidomide and placebo for the study. In addition to Drs. Jacobson and Fox, authors are John S. Greenspan, B.Sc., B.D.S., Ph.D., and Laurie A. MacPhail, D.M.D., Ph.D., both of the Department of Stomatology, University of California, San Francisco; John Spritzler, Sc.D., and Miriam Chernoff, Ph.D., both from the Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Mass.; Nzeera Ketter, M.D., Division of AIDS, NIAID, Bethesda, Md.; John L. Fahey, M.D., Department of Medicine, University of California, Los Angeles; J. Brooks Jackson, M.D., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Md.; Albert W. Wu, M.D., M.P.H., Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.; Guillermo J. Vasquez, M.D., Department of Medicine, University of Puerto Rico Medical School, San Juan; and David A. Wohl, M.D., Department of Medicine, University of North Carolina, Chapel Hill.

Other participating study sites are Mount Sinai Medical Center, New York; University of Hawaii, Manoa; University of Southern California, Los Angeles; Northwestern University, Chicago; University of Washington, Seattle; Stanford University, Palo Alto, Calif.; Harvard Medical School, Boston, Mass.; New York University, New York; Indiana University, Indianapolis; Meharry Medical College, Nashville, Tenn.; University of Pennsylvania, Philadelphia; Case Western Reserve University, Cleveland, Ohio; University of Colorado Health Sciences Center, Denver; University of Rochester, New York; and Albert Einstein College of Medicine, New York.

NIAID, a component of the National Institutes of Health (NIH), conducts and supports research aimed at preventing, diagnosing and treating illnesses such as AIDS and other sexually transmitted diseases, tuberculosis, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services.
Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey J, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, Wohl DA. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. New Engl J Med 1997;336:1487-93.

Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8.

Peterson PK, Hu S, Sheng WS, et al. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 1995;172:1137-40.

Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor-alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-5.

Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon alpha induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37.

Sampaio EP, Sarno EN, Galilly R, Cohn ZA, kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.

Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.

Wulff CH, Hover H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985;112:475-80.

NIAID press releases, fact sheets and other materials are available on the Internet via the NIAID home page at

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to